The U.S. Food and Drug Administration on Thursday has expanded the approval for Jazz Pharmaceuticals' therapy as a maintenance treatment of adult patients with a type of lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback